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A BSTRA CT. 6 -mercaptopurine (6MP) cytotoxicity is caused by thioguanine and methylthioinosine nucleo tides. Thiopurine méthylation occurs to a large extent in vivo and in vitro. In this reaction, S-adenosyl-Lmethionine (AdoMet), produced from methionine and ATP, is converted into S-adenusy l-L-htunocysreine (AdoHcy) which, in turn, is hydrolyzed into homocysteine. Remethylation of homocysteine into methionine is inhibited by methotrexate (MTX). In cultured lymphoblasts, AdoMenAdoHcy ratio and DNA méthylation decrease after incubation with 6MP. The aim of the present study was to investigate the influence of high-do.se 6MP on the méthylation capacity in children with acute lymphoblastic leukemia.
Five patients received 4 courses with high-dose intravenous MTX (5 g • m in 24 hr) immediately followed by high-dose 6MP (1300 mg • m~2 in 24 hr). Five control patients received high-dose MTX and oral 6MP (25 mg • m~2 daily for 8 weeks). Leucovorin rescue was started at .36 hr in both groups.
In the intravenous 6MP group, 6-methylmercaptopurine, its riboside, and 6-methylmercapto-8-hydroxypurine were detectable in plasma in concentrations of 0.3-2.6 |jlM (6MP steady state levels: 11.6 (xM). In red blood cells, mean methylthioinosine nucleotide levels were one third of those of ATP (13,1 nmol/10"). AdoHcy levels (10 pmol/108) remained constant in both groups and AdoMet was not detectable (<20 pmol/10,s). In both groups, plasma homocysteine increased and methionine decreased following administration of MTX. The delay in the recovery of methionine in the intravenous 6MP group after MTX infusion is probably the result-of an increased demand on methyl groups during 6MP infusion. BIOCHKM PHARMACOL 51;9:1165-1171, KEY W ORDS. 6 -mercaptopurine; methotrexate; acute lymphoblastic leukemia; méthylation § is used in the treatment of ALL. It has no intrinsic cytotoxic activity, but is converted into active metabolites intracellularly (Scheme 1). 6MP tlMP which, itself, can be conve MetlMP. Both pathways ferase (EC 2.1.1.67) (TPMT). The TPMT activity is con trolled by a genetic polymorphism and the activity in RBC correlates with that in lymphoblasts, lymphocytes, plate lets, liver, and ki 10 7] . Population studies showed that I ■ '
•' V ** % oi in cytotoxicity in vitro, ei ther by incorporation of thioguanine nucleotides into DNA and RNA [1, 2] or by inhibition of purine de novo synthesis by MetlMP [2, 3] . 6MP is methylated into MeMP and 6MPriboside into MeMPR (Scheme 1). The thiopurine meth-the frequency distribution is trimodal with subjects displaying high activity, 11.1% intermediate activ ity, and 1 out of 300 subjects having undeteetahle TPMT . Thiopurine méthylation requires AdoMet as onor [9] . AdoMet is the universal methyldonor for many methyltransferase reactions of small molecules, DNA, ylation reactions are catalyzed by thiopurine methyltrans-RNA, proteins, and phospholipids, and plays an important role in the regulation of the action of these compounds [10] . Scheme 2 shows the transmethylation pathway with its M M principal metabolites, and methionine. By donation of the methylgroup, AdoMet is converted into AdoHcy, which us hydrolyzed into homo* into cysteine in the transsulfuration pathway or remeth ylated into methionine. Two enzymes catalyze the re meth ylation of homocysteine. sterne met tGTP MetlTP
thiouric acid e metabolism of 6MP. 1, thiopurinemethyL hypoxanthineguanine phosphoribosyltrans-J.8); M 80H P, 6-mercapto«8-hydroxypurine horibosyl-1 'pyrophosphate.
transferase {EC 2.1.1.5) uses betaine as methyldonor and is active only in the liver [11] . 5-Methyltetrahydrofolate ho mocysteine methyltransferase (EC 2.1.1.13) is active in many, if not all, tissues and uses 5-methyltetrahydrofolate as methyldonor [11] . Next to its role in protein synthesis, the essential aminoacid methionine can be activated as methyldonor by formation of AdoMet, using ATP as co substrate [11] . Recently, we reported the effect of 6MP on the principal transmethylation metabolites it vitro [12] . Incubation of Molt-F4 human malignant ALL lymphoblasts with 6MP resulted in a decrease in AdoMet and the AdoMet/AdoHcy ratio, in an increase in AdoHcy and methionine in these cells, and a decreased release of homocysteine into the cul ture medium [12] . The decreased AdoMet/AdoHcy ratio could, theoretically, be caused by a depletion of the AdoMet pool due to its consumption for thiopurine methylation. However, similar effects on AdoMet, AdoHcy, me thionine, and homocysteine were demonstrated after incu bation of these cells with MeMPR, which already contains a methylgroup. Thus, the effects of 6MP and MeMPR on these transmethylation metabolites were ascribed to the reduced conversion of methionine into AdoMet, due to ATPdepletion produced by MetIMP [12] . More recently, we observed that incubation of Molt-F4 lymphoblasts with 6MP or MeMPR resulted in a decrease in the incorporation of [14C] from [14C]-methionine into total DNA [13] , sug gesting that thiopurines can influence DNA méthylation in vitro.
It is well known that quantitative large amounts of 6MP are methylated in vivo. In RBC of ALL patients treated daily with oral 6MP (75 mg • m-2), the median methylthioinosine nucleotide levels were 4-36 nm ol/8* 10 RBC (range 0.25-22.5), compared to the much lower median thioguanine nucleotides levels of 335 pmol/8*108 RBC (range 144-1263) [14] . Methylthioinosine nucleotide lev els were even higher in RBC [15] and mononuclear cells [16] , compared to those of thioguanine, when high doses of 6MP were administered intravenously. Influences of 6MP on the transmethylation metabolites in vivo have not been investigated up to now.
In the present study, we investigated influences of highdose 6MP infusions on méthylation capacity in vivo. In the consolidation treatment of the Dutch Childhood Leukemia Study Group (DCLSG-ALL-8 protocol) ALL patients are randomized for high-dose intravenous 6MP or low-dose oral 6MP. We investigated the oral 6MP group as the control group for the intravenous 6MP group, because both groups also received methotrexate (MTX) infusions. This inhibits dihydrofolate reductase (EC 1.5.1.3), causing a depletion of active tetrahydrofolate compounds (Scheme 2). Thus, it indirectly inhibits folate-dependent reactions, such as remethylation of homocysteine into methionine, purine de novo synthesis, and thymidylate synthesis [17] .
The amounts of 6MP methylated in vivo were investi gated by measurement of the methylated metabolites of 6MP in RBC, plasma, and urine. The influence of the in fusions on the transmethylation metabolites was investi gated by measurement of methionine and homocysteine in plasma and AdoMet, AdoHcy, and purine nucleotides intracellularly. Lymphoblasts were not available for investi- gation, because the patients were in complete remission. We used RBC, because TPMT activity in RBC correlates with that in lymphoblasts and other tissues [4] [5] [6] [7] . RBC can synthesize 5-phosphoribosyl-l-pyrophosphate [18] , an es sential cofactor for the conversion of 6MP into tIMP, but do not manifest an active purine de novo synthesis, as ALL lymphoblasts do [19] .
METHODS
Ten children with ALL were treated in our center accord ing to the DCLSG-ALL-8 protocol with a consolidation (5 g • m-2 in 24 hr, 4 courses in MTX 8 weeks). Leucovorin rescue (Scheme 2) was started at 36 hr after the MTX infusion was begun and continued every 6 hr until MTX plasma levels were less than 0.25 |xM. Five of the 10 patients were randomized for oral 6MP (25 • m 2 daily for 8 weeks, starting 7 days before the first MTX course) and the other 5 received 6MP intravenously (1300 mg • m"2 in 24 hr, from 24 until 48 hr after MTX infusion, 4 courses in 8 weeks). Patient or parental approval was obtained according to the ethical guidelines of our hos- Figure 1 shows the mean levels of the methylated m etabo lites of 6MP in plasma of the intravenous 6MP group. Steady state levels of 6MP and MeMP were 11.6 (sem 1.6) and 0.6 (sem 0.1) |xM, respectively. MeM80HP reached levels of 2.6 (sem 0.5) |xM during the 6MP infusion. U p o n its termination, MeMP and MeM80HP were rapidly cleared from plasma. MeMPR increased slowly during the 6MP infusion and reached levels of 0.3 (sem 0.05) |xM 24 hr after its termination. Methylthioxanthine and methylthiouric acid were not detectable in plasma of these patients. Blood was sampled during the 4 courses of all patients in the oral and intravenous group, before and 24, 28, 48, 52 and 72 hr after the MTX infusion was begun. Plasma and RBC were isolated as described [20] . RBC transfusions, an essential part of the supportive treatment during the inten sive consolidation treatment, were given between the courses, but never during a course. Dithiothreitol was added to plasma, RBC, and urine to prevent oxidation of the thiol groups [20] . Urine was collected during the 24 hr of the 6MP infusion as well as during the next 24 hr, either as a pooled 24'hr sample or as fractionated samples of approx imately 6 hr. In children with nappies, we collected one at the end of the infusion. The methylated metabolites of 6MP and the purine nucleotides were ex tracted and measured with HPLC using ultraviolet absor bance. Detection limits for the methylated metabolites in plasma were 20-50 nM and for MetIMP 11 pmol per 100 (xL injection [20j. A previously indeterminate metabolite of 6MP [20] was identified as MeM8QHP. It was measured as >ther methylthiopurine metabolites and eluted at 30 urine c min [20] . Total homocysteine was measured with HPLC after reduction with sodium borohydride and derivatization with monobromobimane [21] . Methionine was measured as described [12] . AdoMet and AdoHcy were extracted from 200 fxL RBC (2-3.1012 RBC/L 0.9% (w/v) saline with 0.1% (w/v) dithiotreitol) and 200 |xL water with 40 |xL 55% trichloroacetic acid and kept on ice for 10 min. After cen-j trifugation, 300 |xL of the supernatants were washed 3 times with 2 volumes of peroxide-free diethylether to remove the trichloroacetic acid. The samples were flushed with nitro gen to a final volume of 150 |xL. AdoMet and AdoHcy were measured with HPLC [12] at 248, 254, and 260 nm. MetIMP levels were decreased to less than one tenth of the level at 72 hr of the previous course, whereas those of MetIDP were one half and of MetlTP one third. Four chil dren. each received one RBC transfusion between the courses. After this, the methylthioinosine nucleotide levels at the start of the next course were in the same range or higher, compared to those of the previous course. Interindividual variation coefficients of 6MP and the methylated metabolites in plasma and RBC were between 30 and 50%.
RESULTS

Methylated Metabolites of 6MPin Plasma, RBC, and Urine
In urine 6MP, thioxanthine, and thiouric acid were the main metabolites. MeMP, MeM80HP, methylthioxanthine, and methylthiouric acid were not detectable in urine. MeMPR accounted for less than 2% of all ex creted metabolites of 6MP in urine during the 6MP infu sion.
Urine of the oral group was not collected. In plasma and RBC samples of the oral 6MP group at 0, 24, 28,48, 52, and 72 hr, none of the metabolites of 6MP was detectable. Oral 6MP (25 mg • m~2) was given at 7 a.m., whereas blood was sampled at 1 or 5 p.m.. and intravenous 6MP group were in the normal range [22] and remained constant during the MTX and 6MP infusions of all courses. ATP levels were 13.1 (sem 0.9) nmol/108 RBC.
AdoMet and AdoHcy in RBC
AdoMet levels were analyzed in both groups, but were not detectable in any of the samples. The detection limit of AdoMet in RBC is 20 pmoi/108 RBC. AdoHcy levels re mained constant in both groups. Mean AdoHcy levels were 10.8 (sem 1.3) pmol/108 RBC in the intravenous and 9.1 (sem 1.0) pmol/108 RBC in the oral group. (Fig. 3) In both groups, homocysteine levels increased by 130-250% upon administration of MTX and returned to initial values after the start of leucovorin administration. Until 48 hr, there were no significant differences in homo cysteine levels between the groups but, at 52 and 72 hr, they were significantly lower in the intravenous group (ttest, two-tailed, P = 0.03 and 0.002, respectively, df 34, all courses). Methionine levels decreased by 35-50% from 0 to 24 hr during all courses in the oral group and during the third and fourth course in the intravenous group. This de crease in methionine was not present during the first or second course in the intravenous group. After termination of the MTX infusion, methionine levels immediately re turned to initial levels in the oral group. In the intravenous group, methionine levels began to increase 4 hr after ter mination of the 6MP infusion and reached levels 137% above the initial levels at 72 hr. A t 48 and 52 hr, methi onine levels were significantly higher in the oral group (t-test, two-tailed, P = 0.05 and 0.05, respectively, df 33, all courses). At 0, 24, 28, and 72 hr, there were no significant differences. Methionine in unwashed RBC of 10 random 6MP range of 60-200 pmol/108 RBC.
Methionine and Homocysteine in Plasma
DISCUSSION
The importance of a balanced transmethylation pathway and its role in carcinogenesis and malignancy has been stressed by several studies and reviewed by Laird and Jaenisch [23] . The méthylation pattern of DNA of human malignant cells is often characterized by widespread hypomethylation, regional hypermethylation, and elevated ex pression levels of DNA methyltransferase activity. In ani mals, the administration of AdoMet was able to prevent or even reverse the development of tumors, whereas methyldeficient diets were able to induce tumors, which is consis tent with the widespread hypomethylation in tumor D N A [23] . Recently, it was shown that DNA methyltransferase activity contributes substantially to the development of in testinal adenomas [24] . However, it remains unclear wheth er or not changes in the méthylation status (i.e. methionine metabolites, DNA methyltransferase activity, or DNA méthylation) play a causal role in carcinogenesis or are a property of the malignant cell. Even without this knowl edge, the méthylation status might be a target for chemo therapeutic agents. In line with this view, we recently that incubation of Molt F4 lymphoblasts with 6MP resulted in changes in the concentrations of transmethylation metabolites [12] and in DNA méthyl ation [13] .
The present study is the first to investigate the influence of high-dose 6MP on transmethylation metabolites in vivo. Large amounts of methylated thiopurines were detectable in plasma and RBC after high-dose intravenous 6MP, with interpatient variabilities of 30-50% (Fig. 1, 2 ). TPMT ac tivities in peripheral mononuclear cells ranged from 4.6-16.1 IU/109 cells in the present group, demonstrating in termediate and high activity [25] . The genetic polymor phism of TPMT may be partially responsible for the interpatient variability. We could not demonstrate a cor relation between TPMT activity and (methyl)thiopurines, because a high percentage of TPMT assays in mononuclear cells fail due to the lack of cells in leukopenic patients as well as other enzymes involved in thiopurine metabolism (Scheme 1) [25] . Measurement of TPMT in RBC would not be informative because RBC are transfused during the in duction and consolidation treatment. The presence of methylated metabolites of 6MP in urine was less pro nounced, compared to that in plasma and RBC. The ab sence of MeMP and MeMBOHP in urine might be the result of oxidation [26] or glucuronidation [27] of these compounds or of désulfuration of the drug [27] . Methylthioxanthine and methylthiouric acid were not detectable in plasma or urine, which is in concordance with the results obtained from patients treated with 6MP and MeMP [28] and with in vitro data demonstrating that thioxanthine and thiouric acid are inhibitors of TPMT [29] .
In the oral group, 6MP and its metabolites were not detectable in plasma nor RBC. Blood sampling was timed after the start of MTX, as in the intravenous group, and not after 6MP intake. Detection of mono-, di-and triphosphate nucleotides in RBC requires higher intracellular concentra tions of methylthioinosine nucleotides compared to mea surement of MeMP after hydrolysis of the nucleotides. The administered dose (25 mg • m daily for 8 weeks) was one third of the administered daily during 1.5-2-year maintenance therapy of ALL [14] , too low for detection of methylthio inosine nucleotides in the oral group.
The high levels of methylthioinosine nucleotides in RBC in the intravenous group indicate that the transmethylation rate and, thus, the rate of AdoMet synthesis must have been high in RBC. AdoMet levels were below the detection limit in all RBC samples, but the increasing levels of me thylthioinosine nucleotides in RBC after termination of the infusion indicate that sufficient AdoMet was available for this méthylation reaction. In RBC of healthy controls, mean AdoMet levels were 3.5-5.2 (xmol/L packed fresh RBC (30-32) (±10*1012 RBC/1 packed cells). Roughly, | | i these levels are just above our detection limit (20 pmol/10 i j RBC). AdoHcy levels were approximately 10 pmol/10 RBC and remained constant during the MTX and 6MP infusions. In one study, mean AdoHcy levels were one third of those of AdoMet in fresh RBC of healthy subjects [31] whereas, in our study, AdoMet levels were lower than Ado-Hey levels. We used stored RBC from patients treated for leukemia, which may have influenced the difference. We are not aware of a study having been conducted on AdoMet and AdoHcy levels in RBC under similar conditions. Changes in homocysteine and methionine levels in plasma were observed in both groups. The increase in ho mocysteine and the decrease in methionine in plasma after the start of MTX administration could be ascribed to the decreased remethylation of homocysteine, itself the result of the decreased availability of tetrahydrofolate derivatives due to inhibition of dihydrofolate reductase by MTX (Scheme 2). These changes have also been demonstrated by other [33] [34] [35] . A decrease in methionine levels was not detectable during the first two courses in the intravenous group, probably because we did not measure between 0 and 24 hr when the nadir was reached [35] .
After termination of the MTX infusion, methionine and homocysteine levels were different for the two groups. Upon leucovorin administration, homocysteine levels decreased in both groups, but decreased to significantly lower levels at 52 and 72 hr in the intravenous 6MP group. Methionine levels increased immediately to initial levels after termination of the MTX infusion in the oral group, but remained low in the intravenous group during the 6MP infusion, after which they rebounded above initial levels. Because leucovorin, which increases methylation of homo cysteine into methionine, was administered 12 hr after the start of the 6MP infusion, the pure effect of high-dose 6MP on the transmethylation metabolites may be masked. The delay in the recovery of methionine after termination of the MTX infusion in the intravenous group may be the result of the high consumption of methionine for methylation of thiopurines.
Thus, our study in children with ALL in remission shows an effect of high-dose 6MP in plasma (i.e. a delay in the recovery of the decrease in methionine due to MTX). This study does not show evidence for an effect of high-dose 6MP in RBC. This does not exclude the possibility that high-dose 6MP influences the transmethylation metabo lites in the lymphoblasts. However, as all patients were in complete remission during the consolidation treatment, lymphoblasts are not available. It would be worthwhile to investigate the effects of high-dose 6MP alone on the trans methylation pathway in the lymphoblasts immediately after diagnosis, which will probably be done in a window phase of the next DCLSG study (ALL-9). M U *
